71,987 Shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Acquired by Man Group plc

Man Group plc purchased a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 71,987 shares of the company's stock, valued at approximately $1,107,000. Man Group plc owned 0.26% of ClearPoint Neuro as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CLPT. R Squared Ltd acquired a new stake in ClearPoint Neuro in the 4th quarter valued at $32,000. AlphaQuest LLC acquired a new stake in ClearPoint Neuro in the 4th quarter valued at $80,000. Barclays PLC boosted its position in ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after buying an additional 1,109 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in ClearPoint Neuro in the 4th quarter valued at about $93,000. Finally, JPMorgan Chase & Co. boosted its position in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock valued at $110,000 after buying an additional 3,612 shares during the last quarter. Hedge funds and other institutional investors own 30.08% of the company's stock.

ClearPoint Neuro Stock Performance

Shares of NASDAQ:CLPT traded up $0.10 during trading hours on Thursday, hitting $12.19. The stock had a trading volume of 42,943 shares, compared to its average volume of 234,365. The stock's fifty day simple moving average is $12.72 and its 200 day simple moving average is $14.19. ClearPoint Neuro, Inc. has a 1-year low of $5.11 and a 1-year high of $19.22. The firm has a market capitalization of $341.19 million, a price-to-earnings ratio of -17.65 and a beta of 1.03.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The firm had revenue of $8.49 million during the quarter, compared to analyst estimates of $8.21 million. As a group, research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on CLPT. Stifel Nicolaus upped their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Wall Street Zen cut shares of ClearPoint Neuro from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.